CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for transplant patients with advanced skin cancer: immune drugs may control tumors without losing the kidney
Disease control OngoingThis early-phase study tests whether combining immune-boosting drugs (nivolumab and ipilimumab) with a transplant-protecting drug (tacrolimus) can shrink or control advanced skin cancers in kidney transplant recipients. The goal is to treat the cancer while keeping the donated ki…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Radiation boosts immunotherapy in rare skin cancer trial
Disease control OngoingThis study compares the drug pembrolizumab (an immunotherapy that helps the immune system fight cancer) alone versus pembrolizumab plus precise, high-dose radiation (SBRT) in people with advanced Merkel cell carcinoma that has spread. The goal is to see if adding radiation helps …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New hope for tough merkel cell cancer: drug combo trial launches
Disease control OngoingThis study tests whether adding a drug called tuvusertib to the immunotherapy avelumab can slow the growth of advanced Merkel cell cancer that has stopped responding to standard treatment. About 50 adults with this rare skin cancer will receive either the combination or tuvuserti…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:02 UTC